Loading stock data…
STTK
$6.99-0.16 (-2.24%)
Market ClosedLast close May 1
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Shattuck Labs, Inc. in the Healthcare sector is trading at $6.99. The stock is currently near its 52-week high of $8.33, remaining 108.7% above its 200-day moving average. Technical signals show neutral RSI of 55 and bearish MACD signal, explaining why STTK maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.99
Potential Upside
5%
Whystock Fair Value$7.34
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monocl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$585.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.24%
Volume
Today's trading volume
390,127
Recent News
Cantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)
Shattuck Labs, Inc. (NASDAQ:STTK) is one of the best performing small cap stocks so far in 2026. Cantor Fitzgerald initiated coverage of Shattuck Labs, Inc. (NASDAQ:STTK) with an Overweight rating on April 27, telling investors in a research note that the stock’s more than 800% rise over the last 12 months points towards enthusiasm for its […]
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
Investors were pleased to hear that the company's lead pipeline drug is making tangible progress.
Why Shattuck Labs Stock Soared in December
Buttressed by a significant amount of fresh capital, the company is showing progress in the early development of its top investigational drug.
Several Insiders Invested In Shattuck Labs Flagging Positive News
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Analyst Confidence Upbeat on Shattuck Labs (STTK) Amid SL-325 Progress and Earlier Q3 2025 Result
With strong three-month performance and significant upside potential, Shattuck Labs, Inc. (NASDAQ:STTK) secures a spot on our list of the 12 hot penny stocks to invest in right now. Highlighting the SL-325’s Phase 1 readout, expected in Q2 2026, H.C. Wainwright’s Joseph Pantginis reiterated a “Hold” rating on Shattuck Labs, Inc. (NASDAQ:STTK) on November 7, […]